GlassScriptPhysician profile
John B Jiu
NPI 1871568808
$3,618.72
in general payments reported to CMS, 2019-2025
21 companies · $627 in 2025
The $627 reported for 2025 was more than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $48.83 · 2021: $462 · 2022: $391 · 2023: $889 · 2024: $931 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,911 · Travel and Lodging: $285 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,911.34 |
| Travel and Lodging | $284.61 |
| Education | $250.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $680.81 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $623.24 | 2021-2025 | Nucala |
| Inspire Medical Systems, INC. | $594.77 | 2023-2025 | Inspire |
| Intersect Ent, INC. | $371.97 | 2019-2021 | |
| Genzyme Corporation | $252.92 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $210.32 | 2024-2025 | Voquezna |
| Aerin Medical INC. | $136.97 | 2022-2025 | |
| Medtronic, INC. | $109.06 | 2024 | Stealthstation S8 Platform |
| Acclarent, INC | $105.35 | 2019-2023 | Relieva Ultirra |
| Stryker Corporation | $94.46 | 2019-2023 | Claw II |
| Optinose US, INC. | $83.08 | 2019-2022 | |
| Organogenesis INC. | $66.03 | 2021-2023 | Puraply |
| Neurent Medical Limited | $57.03 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Sanofi-Aventis U.S. LLC | $52.99 | 2024 | |
| Hikma Pharmaceuticals USA | $48.29 | 2023-2024 | Ryaltris |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $46.46 | 2022 | |
| Merck Sharp & Dohme LLC | $21.93 | 2025 | Keytruda Qlex, Keytruda |
| Baudax Bio INC. | $21.70 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.50 | 2025 | Tezspire |
| Arbor Pharmaceuticals, INC. | $13.44 | 2019 | |
| Olympus America INC. | $12.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.